Wallace, Rebecca, Bliss, Carly M. and Parker, Alan L.  ORCID: https://orcid.org/0000-0002-9302-1761
2024.
The immune system - A double-edged sword for adenovirus-based therapies.
Viruses
16
(6)
, 973.
10.3390/v16060973
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Pathogenic adenovirus (Ad) infections are widespread but typically mild and transient, except in the immunocompromised. As vectors for gene therapy, vaccine, and oncology applications, Ad-based platforms offer advantages, including ease of genetic manipulation, scale of production, and well-established safety profiles, making them attractive tools for therapeutic development. However, the immune system often poses a significant challenge that must be overcome for adenovirus-based therapies to be truly efficacious. Both pre-existing anti-Ad immunity in the population as well as the rapid development of an immune response against engineered adenoviral vectors can have detrimental effects on the downstream impact of an adenovirus-based therapeutic. This review focuses on the different challenges posed, including pre-existing natural immunity and anti-vector immunity induced by a therapeutic, in the context of innate and adaptive immune responses. We summarise different approaches developed with the aim of tackling these problems, as well as their outcomes and potential future applications.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine |
| Publisher: | MDPI |
| ISSN: | 1999-4915 |
| Funders: | Cancer Research UK |
| Date of First Compliant Deposit: | 18 June 2024 |
| Date of Acceptance: | 14 June 2024 |
| Last Modified: | 20 Jun 2024 11:35 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/169870 |
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions